Evaluation of Safety and Performance of Intraoperative Detection of Light Signals During Electrosurgical Breast Cancer Resection
1 other identifier
interventional
24
1 country
1
Brief Summary
This monocentric early feasibility first in human study is intended to evaluate safety and performance of intraoperative detection of light signals during electrosurgical breast cancer resection. In consequence the data should also be taken to adapt technical features according to the findings. The study results will be utilized to design and to calculate the sample size for future pivotal studies after finalizing this study and to adapt the technical features of the system and/ or device. In the future pivotal study, the effectiveness of method and the reduction in R1 resection rate will be assessed with the final goal to provide continuous or real-time information about the tissue type that is currently cut. The primary endpoint for this first in human feasibility study is the percentage of patients with no serious adverse event related to the investigational device. After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. During the second visit (V2) they will receive the treatment procedure with the investigational medical device (IMD). The follow up visit (V3) will be performed up to 7 days after the treatment procedure at the day of discharge from the hospital.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable breast-cancer
Started Sep 2023
Shorter than P25 for not_applicable breast-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 24, 2023
CompletedFirst Posted
Study publicly available on registry
August 31, 2023
CompletedStudy Start
First participant enrolled
September 26, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 29, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 29, 2024
CompletedSeptember 5, 2024
September 1, 2024
10 months
August 24, 2023
September 2, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Safety, feasibility and performance
The primary endpoint for this first in human feasibility study is the percentage of patients with no serious adverse event related to the investigational device.
11 days
Study Arms (1)
Intraoperative detection of light signals during electrosurgical breast cancer resection
OTHERParticipants undergo electrosurgical breast cancer resection while light signals are detected intraoperatively
Interventions
The device will be used for tumor resection of breast cancer and for the collection of optical data that could be ultimately used for providing additional information.
Eligibility Criteria
You may qualify if:
- Female patient with primary invasive breast cancer (NST or NST with DCIS component, including endocrine pretreatment according to standard of care therapy at the study site)
- Solid tumor size ≥ 15 mm at screening, on sonography imaging
- Breast conserving surgery
- ≥ 18 years of age
- Ability to provide written informed consent
You may not qualify if:
- Neoadjuvant chemotherapy
- Bilateral breast conserving surgery
- Invasive lobular carcinoma, DCIS, LCIS
- Suspicion of extensive DCIS component of NST tumor
- Diagnosis of recurrent breast cancer
- Previous radiotherapy
- Patient is pregnant or lactating
- Patient is wearing active implant (cardiac pacemaker, internal defibrillator, other active implant), passive implants (hip arthroplasties, tooth implants etc.) are allowed at the discretion of the principal investigator
- According to physicians' assessment, patient is not able to follow study protocol (e.g., due to cognitive disease) or is not able to understand the nature, objectives, benefits, implications, risks and inconveniences of the clinical investigation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department for Women's Health
Tübingen, 72076, Germany
Related Publications (1)
Spether D, Scharpf M, Hennenlotter J, Schwentner C, Neugebauer A, Nussle D, Fischer K, Zappe H, Stenzl A, Fend F, Seifert A, Enderle M. Real-time tissue differentiation based on optical emission spectroscopy for guided electrosurgical tumor resection. Biomed Opt Express. 2015 Mar 24;6(4):1419-28. doi: 10.1364/BOE.6.001419. eCollection 2015 Apr 1.
PMID: 25909025BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Markus Hahn, Prof.Dr. Med.
Department for Women's Health, Tuebingen, Germany
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 24, 2023
First Posted
August 31, 2023
Study Start
September 26, 2023
Primary Completion
July 29, 2024
Study Completion
July 29, 2024
Last Updated
September 5, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share